Archives
- 2025-11
- 2025-10
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-08
-
To identify and characterize new possible molecular targets
2019-07-26

To identify and characterize new possible molecular targets, the mechanisms of various kinds of TCDD toxicities that occur by abnormal regulation in the downstream of AhR signals have been studied (Yoshioka et al., 2011). Experimental evidence has revealed that prostanoids (i.e., prostaglandins and
-
br Substrate characterization of candidate peptide reporters
2019-07-26

Substrate characterization of candidate peptide reporters in a library Measurement of resistance to intracellular proteases Use of capillary zone electrophoresis for assay readout Selection of lead peptide from small library screen Characterization of final reporter Additional modif
-
o-Phenanthroline solubility br Results br Discussion Oxyster
2019-07-26

Results Discussion Oxysterols and EBI2 have received growing attention in the field of immunology, with works highlighting an important role for EBI2 in immune cell migration. However, these studies are mainly limited to animal models (Chalmin et al., 2015, Hannedouche et al., 2011, Kelly et a
-
These reactions are used to account
2019-07-25

These reactions are used to account for variations in protein solubility or vesicle recovery. For example, with DGKθ we have found it necessary to maintain the purified enzyme in a solution of 0.01% DDM (DGK-D dilution buffer) in the control reaction to prevent enzyme loss due to aggregation or adhe
-
Introduction Rotavirus RV a member
2019-07-25

Introduction Rotavirus (RV), a member of Reoviridae family, is a non-enveloped virus which has a double-stranded RNA genome of 11 segments surrounded by three concentric protein layers. It has been reported to cause estimated 25% of moderate-to-severe illnesses (Kotloff et al., 2013) and 30% of to
-
Primary human GBM neurospheres expressed high levels of the
2019-07-25

Primary human GBM neurospheres expressed high levels of the metabolic enzyme fatty acyl-CoA synthetase VL3 (ACSVL3) that were associated with CSCs self-renewal and tumorigenic capacity. ACSVL3 knockdown significantly decreased ALDH levels, indicating its contribution to cell metabolism and maintenan
-
pmsf Almost of drugs in the
2019-07-25

Almost 75% of drugs in the market undergo deactivation though oxidation, reduction or hydrolysis by cytochrome P450 (CYP) enzymes, and then, either directly or by facilitated excretion from the body (Guengerich, 2008). The CYP3A subfamily is of particular interest because of its broad substrate spec
-
In the present study we did not examine whether the
2019-07-25

In the present study, we did not examine whether the CpG site-specific COMT methylation are associated with any genetic variants in response to E2, GEN or SFN. Some studies suggest that oxidative DNA damage causes genetic variation which may induce epigenetic changes that lead to gene silencing (Kho
-
br Conclusion This patient was hypercoaguable as
2019-07-25

Conclusion This patient was hypercoaguable as evidenced by a lower extremity DVT, pulmonary emboli, and a splenic infarct. Excluding acute CMV infectious mononucleosis, she had no disorders predisposing to splenic infarcts.4, 5 In this case, CMV infectious mononucleosis was accompanied by CMV lun
-
Activating GSK signaling to inhibit PK
2019-07-25

Activating GSK3β signaling to inhibit PK signaling during ischemia/reperfusion (I/R) is protective of WM ischemic injury. Glycogen synthase kinase (GSK3), which was the first substrate identified for AKT [44], is inhibited by AKT phosphorylation at positions S9 and S21 [45]. When GSK3β is active, it
-
gw501516 chemical br Acknowledgements This work was
2019-07-25

Acknowledgements This work was supported by grants from National Natural Science Foundation of China (31772196 and 31301693), the Chinese Ministry of Agriculture (the 948 project no. 2014-S10). Rothamsted Research also receives grant-aided support from the UK Biotechnology and Biological Sciences
-
br Results br Discussion Fetal development occurs under
2019-07-25

Results Discussion Fetal development occurs under conditions of low oxygen tension and steady maternal glucose such that physiologic systems including the pancreas are functionally poised in the prenatal state. Postnatally, oxidative metabolism becomes dominant and intermittent feeding exposes
-
br Material and methods br Results br
2019-07-24

Material and methods Results Discussion In vitro evidence indicates that LAS191859 is a potent CRTh2 antagonist as demonstrated in GTPγS binding studies with potency in the low nanomolar range and in addition it demonstrates a long receptor residence time. This potency is also maintained in
-
One significant finding in this study was the
2019-07-24

One significant finding in this study was the overexpression of a protein identified as LysM domain/BON superfamily protein [29], [30]. This protein was highly overexpressed in the meropenem-treated condition. InterProScan analysis revealed that the LysM domain/BON superfamily protein consisted of t
-
The UI compo http www apexbt com
2019-07-24

The UI components used in our proposal are called COTSgets, from COTS (Commercial Off-The-Shelf) [28] and gadgets (understood as any software that can work alone or as a piece of the architecture). A COTS component is any coarse-grained component developed by third parties available for building mor
15795 records 975/1053 page Previous Next First page 上5页 971972973974975 下5页 Last page